Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 2 1Phase 1/2 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Genitourinary 3Dermatologic 3Head & Neck 2Gastrointestinal 2Breast 2Lymphoid 1Gynecologic 1

Conditions

Melanoma 25Leukemia, Lymphocytic, Chronic, B-Cell 10Breast Neoplasms 10Recurrence 9Leukemia, Myeloid, Acute 9Carcinoma, Non-Small-Cell Lung 9Neuroblastoma 8Lymphoma, Non-Hodgkin 8Neoplasms 7Ovarian Neoplasms 6Neoplasm Metastasis 6Leukemia 6Colorectal Neoplasms 6Carcinoma, Renal Cell 6Uveal Melanoma 5Myelodysplastic Syndromes 5Multiple Myeloma 5Lymphoma, Follicular 5Lymphoma 5Lung Neoplasms 5Head and Neck Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Mantle-Cell 4Lymphoma, B-Cell, Marginal Zone 4Lymphoma, B-Cell 4Hematologic Neoplasms 4Carcinoma, Squamous Cell 4Carcinoma, Hepatocellular 4Uterine Cervical Neoplasms 3Unspecified Adult Solid Tumor, Protocol Specific 3

Interventions

pembrolizumab 7fludarabine 4Nivolumab 4Cyclophosphamide 4Radiation 3Interleukin-2 3talimogene laherparepvec 2poly ICLC 2budigalimab 2aldesleukin 2Radiotherapy 2Ipilimumab 2Everolimus 2CTLA-4 Antigen 2zimberelimab 1venetoclax 1veliparib 1vatalanib 1tocilizumab 1temsirolimus 1rovalpituzumab tesirine 1prednylidene 1pentetreotide 1lorvotuzumab mertansine 1glucopyranosyl lipid-A 1flt3 ligand protein 1deltacortene 1cixutumumab 1avelumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Carcinoma, Merkel Cell × Interleukin-2 × Clear all
NCT04551885 2023-09-21

FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors

Fate Therapeutics

Phase 1 Terminated
12 enrolled
BreastDermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Merkel Cell, Triple Negative Breast Neoplasms

NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

NCT04596033 2022-07-15

TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy

Genocea Biosciences, Inc.

Phase 1 Terminated
49 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Melanoma, Neoplasms, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡